Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Titel:
Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors
Auteur:
Kris, M.G. Camidge, D.R. Giaccone, G. Hida, T. Li, B.T. O'Connell, J. Taylor, I. Zhang, H. Arcila, M.E. Goldberg, Z. Jänne, P.A.